维生素D补充对成人代谢综合征参数的影响:一项系统评价随机对照试验,探讨基线维生素D状态和补充剂量的作用。
完整摘要 · 中文译文
引言:代谢综合征(MetS)是一组心脏代谢异常,包括中心性肥胖、血糖异常、高血压和血脂异常。维生素D缺乏在患有MetS的成年人中高度普遍,并可能促进胰岛素抵抗、炎症和不良血脂谱。尽管已有报道称维生素D补充可改善MetS参数,但关于这些效应是否因基线维生素D状态或补充剂量而异的信息有限,而这些信息对临床决策至关重要。 方法:本系统综述评估了口服维生素D补充对成年人MetS组分的影响,并检验了治疗效果是否因基线维生素D状态和补充剂量而呈现差异。按照PRISMA指南,对PubMed/MEDLINE、Embase、Web of Science和CENTRAL进行了全面检索。鉴于预期纳入试验之间存在临床和方法学异质性,预先计划进行叙述性综合而非荟萃分析。使用Cochrane协作网偏倚风险评估工具评估偏倚风险。符合条件的随机对照试验(RCT)包括那些评估口服维生素D补充至少8周、对象为诊断为代谢综合征或至少存在5项MetS组分中3项的成年人的试验。此外,对照组包括安慰剂或仅饮食指导对照。关注结局包括腰围、甘油三酯、HDL-胆固醇、血压、空腹血糖、稳态模型评估胰岛素抵抗(HOMA-IR)、血 糖化血红蛋白(HbA1c)和体重指数(BMI)。 结果:八项随机对照试验(634名参与者)符合全部纳入标准,被纳入叙述性综合。维生素D补充在各试验中一致地提高了血清25(OH)D浓度。部分试验报告甘油三酯和胰岛素抵抗指标有显著改善,个别研究报告部分炎症标志物、腰围和BMI有改善,而血压、HDL胆固醇和空腹血糖在大多数试验中未见一致变化。在基线维生素D缺乏的参与者中以及在使用较高补充剂量的试验中,结果最为有利,但这些模式属于探索性的,因为没有任何一项试验针对正式亚组比较进行了效能计算。偏倚风险评估表明,八项评估试验中有七项在至少一个领域存在一些担忧或高偏倚风险,限制了证据的总体确定性。 结论:维生素D补充对特定MetS组分显示出轻微益处,尤其是在维生素D缺乏的成人中,但各试验和代谢参数之间的效应不一致。研究设计、给药策略和人群特征的显著变异性限制了确定性结论。需要具备足够效能、标准化的随机试验来阐明维生素D在代谢综合征管理中的作用。 系统综述注册号:CRD420261421121。
完整摘要 · 英文原文
INTRODUCTION: Metabolic syndrome (MetS) is a cluster of cardiometabolic abnormalities including central obesity, dysglycemia, hypertension, and dyslipidemia. Vitamin D deficiency is highly prevalent among adults with MetS and may contribute to insulin resistance, inflammation, and adverse lipid profiles. Although vitamin D supplementation has been reported to improve MetS parameters, limited information is available on whether these effects differ by baseline vitamin D status or supplementation dose, information essential for clinical decision-making. METHODS: This systematic review evaluated the effect of oral vitamin D supplementation on MetS components in adults and examined whether treatment effects appeared differ according to baseline vitamin D status and supplementation dose. A comprehensive search of PubMed/MEDLINE, Embase, Web of Science, and CENTRAL was conducted following PRISMA guidelines. Given the anticipated clinical and methodological heterogeneity across eligible trials, a narrative synthesis rather than meta-analysis was planned a priori. Risk of bias was assessed using the Cochrane Collaboration Risk of Bias Tool. Eligible RCTs included those evaluating oral vitamin D supplementation for at least 8 weeks in adults diagnosed with metabolic syndrome or presenting at least 3 of 5 MetS components. In addition, comparator groups included placebo or dietary-instruction-only controls. Outcomes of interest included waist circumference, triglycerides, HDL-cholesterol, blood pressure, fasting glucose, homeostatic model assessment of insulin resistance (HOMA-IR), glycated hemoglobin (HbA1c), and body mass index (BMI). RESULTS: Eight randomized controlled trials (634 participants) met the full eligibility criteria and were included in the narrative synthesis. Vitamin D supplementation consistently increased serum 25(OH)D concentrations across trials. Significant improvements were reported in triglycerides and insulin resistance indices in a subset of trials, and in selected inflammatory markers, waist circumference, and BMI in individual studies, while blood pressure, HDL-cholesterol, and fasting glucose showed no consistent change across the majority of trials. Findings were most favorable among participants with baseline vitamin D deficiency and in trials using higher supplementation doses, although these patterns are exploratory, as no trial was powered for formal subgroup comparison. Risk-of-bias assessment indicated that seven of the eight evaluated trials had some concerns or high risk of bias in at least one domain, limiting the overall certainty of the evidence. CONCLUSIONS: Vitamin D supplementation shows slight benefit for specific MetS components, particularly among vitamin D-deficient adults, but effects were inconsistent across trials and metabolic parameters. Substantial variability in study design, dosing strategies, and population characteristics limits definitive conclusions. Adequately powered, standardized randomized trials are needed to clarify vitamin D's role in metabolic syndrome management. SYSTEMATIC REVIEW REGISTRATION: CRD420261421121.